Addressing the Symptom Burden of Patients With MPN


The expert who created an assessment tool to help patients with myeloproliferative neoplasms explain their symptoms to their care ream shares how the idea came to fruition.

Patients with myeloproliferative neoplasms (MPNs) will have a wide range of symptoms that are sometimes hard to quantify and properly address within a patient’s treatment process. Which is why a simple tool like the MPN symptom assessment form is invaluable for patients and their care team. Behind this assessment form is, Dr. Robyn Scherber, who is one of CURE®’s 2019 MPN Heroes® and was recognized for her research contributions, as well as her advocacy efforts in addressing patient symptom burden.

During the event, CURE® spoke with Scherber, a physician in the hematology department of the UT Health San Antonio Mays Cancer Center, about her efforts in the MPN field and how the form came to be.


So my early work was really focused on creating different symptom assessment forms for patients with MPN. So we first had the MFSAF, the myelofibrosis symptom assessment form, and we went on to expand that to include polycythemia vera and essential thrombocytopenia patients.

That expanded form was called the myeloproliferative neoplasms symptom assessment form. We also tried to kind of bring it down to into just a few items, so it wasn't so broad, and that's when we created what's called the total symptom score or MPN10. To date, that's actually been incorporated into the large guidelines that we have to treat patients with MPN — the National Comprehensive Cancer Network guidelines.

It has also been used in almost all of the clinical trials to date in one form or another. I feel very honored, it's become a benchmark for success in different drugs to see whether or not they are impacting symptom burden in a meaningful way.

Related Videos
Jessica McDade, B.S.N., RN, OCN, in an interview with CURE
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
A man with a dark gray button-up shirt with glasses and cropped brown hair.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE